In a 11-min video, five experts in addiction explain why KT-110 is a game changer and why it is a hope for millions of AUD patients.   Henri-Jean Aubin is Professor of Psychiatry and Addictology at Hôpital Pitié-Salpétrière in Paris, France. He was the Principal Investigator in KT-110 phase 2 trial. Karl Mann is Professor Emeritus at Central Institute of Mental Health, University of Heidelberg, Germany. Wim van den Brink is Professor Emeritus of Psychiatry and Addiction at Academic Medical Center, University of Amsterdam, The Netherlands. Antoni Gual is Head of the Addictions Unit Neurosciences Institute at University of Barcelona, Spain. Raymond Anton is Professor Emeritus of Psychiatry and Addictions at Medical University of South Carolina, USA.

Kinnov Therapeutics was present at the 37th ECNP congress https://www.ecnp.eu/congress2024/ECNPcongress, in Milan 21-24 Sep, 2024. Within the scope of ECNP’s New Medications Symposium, Prof Henri-Jean Aubin and Julien Guiraud were invited to present results of phase 2 clinical trials. The annual ECNP Congress is Europe's premier scientific meeting for disease-oriented brain research. Prof Henri-Jean Aubin was Principal Investigator for phase 2 clinical trial. Julien Guiraud (Vergio Consulting) is co-author of phase 2 clinical trial publication.

We are thrilled to announce our ground breaking Phase II results published in Addiction Journal (April 10th 2024) entitled: Prazosin and cyproheptadine in combination in the treatment of alcohol use disorder: A randomized, double-blind, placebo-controlled trial. https://onlinelibrary.wiley.com/doi/10.1111/add.16484 The article demonstrates the positive results of Kinnov Therapeutics phase II trial in the reduction of total alcohol consumption in patients with severe alcohol use disorder. Addiction is the official and reference journal of the Society for the Study of Addiction, and has been in publication since 1884. It publishes peer-reviewed research reports on pharmalogical and behavioural addictions, bringing together research conducted within many different disciplines.

Kinnov Therapeutics (KT) meets a new important milestone in galenic. To overcome the difficult observance of alcoholic patients, KT has developed and patented an innovative galenic form allowing a single daily intake of KT-110. This major challenge to deliver two active molecules with different PK and pharmacological profiles, has been met allowing application to ANSM* for evaluation of the new galenic on patients. The dossier has been accepted in March triggering the assays on the new formula on 8 patients. Results are expected for June 2024.

*ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé) is the French Drug Regulatory Authority.

CORDIS platform shares results of Kinnov projects funded by European Commission within the scope of the Horizon 2020 program: https://cordis.europa.eu/project/id/873252/reporting/fr CORDIS is the main source of results of European Commission's innovation and research funding programs. Horizon 2020 is the funding program granted to Kinnov in 2019 for their projects on alcohol use disorders (Cocktail phase 2 study and bilayer development). Within the scope of this funding program, covering the period between October 2019 and March 2022, Kinnov kept EU regularly informed about status of activities through periodic reporting. Reporting shared by CORDIS is the third and last one, updating EU on period from September 2021 to March 2022.

(more…)

A phase 2 trial based on the simultaneous blockade of two neurobiological pathways has shown exciting results in patients with severe alcohol use disorder.

Un essai de phase 2 reposant sur le blocage simultané de deux voies neurobiologiques a obtenu des résultats enthousiasmants chez des patients atteints d’un trouble sévère de l’usage de l’alcool. Actualités Medscape, 23 juin 2022

Kinnov-Therapeutics Announces Positive Phase 2 Outcome: Key Milestone with Lead Drug KT-110 for Alcohol Use Disorder.

Kinnov-Therapeutics has reached a key clinical milestone for treatment of Alcohol Use Disorder with a Phase 2 clinical study for its game changing drug KT-110. Alcoholism is a major public health issue with a strong unmet medical need.

Link to online article